Cooper Companies, Inc. (The) (NYSE: COO) and TearLab Corporation (NASDAQ:TEAR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitabiliy, institutional ownership, valuation, risk and dividends.


This table compares Cooper Companies, Inc. (The) and TearLab Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cooper Companies, Inc. (The) 16.02% 15.88% 9.62%
TearLab Corporation -61.14% N/A -60.70%


Cooper Companies, Inc. (The) pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. TearLab Corporation does not pay a dividend. Cooper Companies, Inc. (The) pays out 0.9% of its earnings in the form of a dividend.

Valuation and Earnings

This table compares Cooper Companies, Inc. (The) and TearLab Corporation’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Cooper Companies, Inc. (The) $2.05 billion 5.83 $635.85 million $6.67 36.70
TearLab Corporation $27.95 million 0.50 -$9.93 million ($3.33) -0.73

Cooper Companies, Inc. (The) has higher revenue and earnings than TearLab Corporation. TearLab Corporation is trading at a lower price-to-earnings ratio than Cooper Companies, Inc. (The), indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Cooper Companies, Inc. (The) has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, TearLab Corporation has a beta of 2.67, indicating that its share price is 167% more volatile than the S&P 500.

Insider and Institutional Ownership

98.1% of Cooper Companies, Inc. (The) shares are held by institutional investors. Comparatively, 29.8% of TearLab Corporation shares are held by institutional investors. 1.6% of Cooper Companies, Inc. (The) shares are held by company insiders. Comparatively, 11.6% of TearLab Corporation shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Cooper Companies, Inc. (The) and TearLab Corporation, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cooper Companies, Inc. (The) 0 3 6 0 2.67
TearLab Corporation 0 1 4 0 2.80

Cooper Companies, Inc. (The) currently has a consensus price target of $238.00, suggesting a potential downside of 2.77%. TearLab Corporation has a consensus price target of $5.75, suggesting a potential upside of 137.60%. Given TearLab Corporation’s stronger consensus rating and higher probable upside, analysts plainly believe TearLab Corporation is more favorable than Cooper Companies, Inc. (The).


Cooper Companies, Inc. (The) beats TearLab Corporation on 10 of the 15 factors compared between the two stocks.

Cooper Companies, Inc. (The) Company Profile

The Cooper Companies, Inc. is a global medical device company. The Company operates through two business units: CooperVision, Inc. and CooperSurgical, Inc. CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses. CooperVision services three primary regions: the Americas; Europe, the Middle East and Africa (EMEA), and Asia Pacific. CooperVision offers spherical, aspherical, toric, multifocal and toric multifocal lens products in various modalities. CooperVision’s products are primarily manufactured at its facilities located in the United Kingdom, Puerto Rico, Hungary, Costa Rica and New York. CooperSurgical offers an array of products and services focused on advancing the health of families through a portfolio of products and services focusing on women’s health, fertility and diagnostics.

TearLab Corporation Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor’s office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Receive News & Stock Ratings for Cooper Companies Inc. (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc. (The) and related stocks with our FREE daily email newsletter.